





PHARMACEUTICAL 2023

BridgeBio Pharma Inc.
Rank 395 of 446



The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is -211%, being 254% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	548,853
Cost of Goods Sold	0
Intangible Assets	28,712
Liabilities, Current	121,428
Liabilities, Non-Current	469,910
Other Assets	30,902
Other Compr. Net Income	3,273
Other Expenses	47,199
Other Liabilities	1,276,622
Other Net Income	27,550
Other Revenues	77,648
Property and Equipment	14,569
Research and Development	399,462
Selling, General and Administrative Expense	143,189

Output Variable	Value in 1000 USD
Assets	623,036
Liabilities	1,867,960
Expenses	589,850
Revenues	77,648
Stockholders Equity	-1,244,924
Net Income	-484,652
Comprehensive Net Income	-483,016
Economic Capital Ratio	-211%